Hhlr Advisors LTD. Has $660,000 Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Hhlr Advisors LTD. reduced its holdings in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 97.6% in the third quarter, HoldingsChannel.com reports. The fund owned 76,247 shares of the company’s stock after selling 3,045,442 shares during the quarter. Hhlr Advisors LTD.’s holdings in Aligos Therapeutics were worth $660,000 at the end of the most recent quarter.

Separately, Armistice Capital LLC boosted its position in shares of Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after purchasing an additional 363,000 shares in the last quarter. 60.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Stock Up 11.0 %

Aligos Therapeutics stock opened at $25.51 on Friday. The company has a market capitalization of $91.58 million, a PE ratio of -1.92 and a beta of 2.11. Aligos Therapeutics, Inc. has a 12-month low of $6.76 and a 12-month high of $30.00. The firm’s fifty day moving average is $11.83 and its 200 day moving average is $12.67.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same quarter in the prior year, the company posted ($10.25) EPS. Sell-side analysts expect that Aligos Therapeutics, Inc. will post -10.36 EPS for the current fiscal year.

Aligos Therapeutics Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).